Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Roper Hospital — Charleston, South Carolina
- Lowcountry Hematology Oncology PA-North Charleston — Charleston, South Carolina
- Bon Secours Saint Francis Hospital — Charleston, South Carolina
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
- Gibbs Cancer Center-Pelham — Greer, South Carolina
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in South Carolina: - Medical University of South Carolina Health Lancaster Medical Center — Lancaster, South Carolina
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in South Carolina: - USA03-0 — Charleston, South Carolina
Phase 2 Recruiting Academic/Other
This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a…
Sponsor: Medical University of South Carolina
NCT ID: NCT06424067
Sites in South Carolina: - Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT06179069
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in South Carolina: - Dren Investigational Site — Greenville, South Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Beaufort Memorial Hospital — Beaufort, South Carolina
- Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina: - Massive Bio SYNERGY-AI site — Greenville, South Carolina
Recruiting Industry
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and di…
Sponsor: Tempus AI
NCT ID: NCT05236114
Sites in South Carolina: - The Medical University of South Carolina — Charleston, South Carolina
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in South Carolina: - Research Site — West Columbia, South Carolina
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in South Carolina: - Medical University of South Carolina (MUSC) — Charleston, South Carolina
- McLeod Health — Florence, South Carolina
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Carolina Blood and Cancer Care Associates — Rock Hill, South Carolina
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- McLeod Health — Florence, South Carolina
NA Recruiting Federal
Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, …
Sponsor: VA Office of Research and Development
NCT ID: NCT06538636
Sites in South Carolina: - Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina